Home > SANTE - SCIENCES DE LA VIE > Industrie Pharmaceutique > Emerging pharmaceutical ...
AUTRES RESSOURCES
 
AUTRES SECTEURS
 
TOUS NOS SECTEURS
 
Industrie Pharmaceutique > Etude de marché sectorielle
 Emerging pharmaceutical markets Argentina and Mexico
€ 6 080,00
Editeur :
Datamonitor
Langue :
Anglais
Date de publication :
Mars 2008
Taille du document :
106
Autres informations :
Description , Table des matières
 
Recevez cette publication aujourd'hui !
Plus d'information ?
+33 437 37 1637
 
Rechercher d'autres rapports et études à commander

Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux


Rapports privés en relation
Pfizer's Recent Takeover
15 pages | Juillet 2002 |
On 15th July 2002, Pfizer announced the acquisition of Pharmacia in a stock-for-stock transaction valued at $60 billion, expanding the company's core strengths in pharmaceuticals and health care.
300,00 €
 
 
Healthcare In Northern Ireland
52 pages | Mai 2000 |
The Northern Ireland Presentation Includes:- The Structure Of The Health Service In Northern Ireland- Total Expenditure On Health & Personal Social Services- Number Of Inpatient Beds, BY Area- Occ
327,00 €
 
 
The Pharmaceutical Mergers and Acquisitions Outlook 2001
128 pages | Octobre 2001 |
Pharmaceutical companies have recently undertaken extensive M&A activity to either build critical mass, create organic growth or through strategic alliances to build virtual mass.
The Pharmaceu
1 200,00 €
 
 
Pharmaceutical Mergers & Aquisitions: the third wave
160 pages | Février 1999 |
Historical assessment : The report identifies the factors that have driven the two historical waves of M&A activity, and analyses the relative importance of these factors through case studies.
795,00 €
 
 
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused
955,00 €
 
 
Global Pharmaceutical: a market, company and disease analysis
150 pages | Octobre 1998 |
What will drive pharmaceutical market growth into the 21st Century? What are the key challenges facing pharmaceutical manufacturers? Who are the market leaders in each sector? What strategies ar
795,00 €
 
 
Healthcare: Germany
106 pages | Octobre 2000 |
Compare the changes in expenditure between the different healthcare sectors in Germany · Understand the main factors affecting demand for healthcare services in Germany · Examine the
578,54 €
 
 
Healthcare In Scotland
52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E
327,00 €
 
 
The Cardiovascular Outlook 1998-2010
186 pages | Août 1999 |
In 1998, the global cardiovascular market expanded by 7.2%, growing in value from $60bn in 1997 to almost $65bn in 1998.
Market expansion is being driven by expanding prevalent populations in t
795,00 €
 
 
Healthcare In Southern Ireland
40 pages | Mai 2000 |
The Republic Of Ireland Presentation Includes:- The Structure Of The Health Service In The Republic Of Ireland- Capital Expenditure On Health Care In The Republic Of Ireland- Number Of Publicly Funded
327,00 €
 
 
 
Autres secteurs en relation
Rechercher d'autres rapports!
 
 
 
Présentation de l'étude de marché - Description & Table des matières
 Emerging pharmaceutical markets Argentina and Mexico

Introduction

Latin American countries have attracted a lot of attention recently. With their economies currently stable, their geographic location and low-cost is ideal for investors. In addition, having such a high and varied population eases recruitment for clinical trials, and the demographics show there is a very high need for pharmaceuticals.

Scope

  • Overview of the key trends driving the pharmaceutical market growth
  • Analysis of key healthcare system characteristics impacting the pharmaceutical market
  • Analysis of pharmaceutical market dynamics in Argentina and Mexico
  • Overview of key pharmaceutical players in Argentina and Mexico


  • Highlights

    Although both the Argentinean and the Mexican markets have been growing, their growth is attributed to different reasons. The Argentinean pharmaceutical market has been growing mainly based on growing sales volume, while growth of the Mexican market is mainly driven by growing prices.

    The Mexican market is dominated by foreign companies with few domestic players. The Argentinean market is dominated by domestic branded generics firms, due to the economic crisis which led to many foreign companies to sell their plants in Argentina, thus allowing the domestic firms to gain over their market share.

    Sales of pharmaceutical categories in both countries are very similar to the West thus opening growth opportunities for foreign companies. However, sales of oncology drugs are low in both countries; and Mexico has higher sales of anti-infective drugs indicating that these markets still have scope for further development and growth.

    Reasons to Purchase

  • Identify the healthcare needs in Argentina and Mexico
  • Understand the barriers and drivers for entering these markets
  • Gain insight into pharmaceutical dynamics of Argentina and Mexico


  •  

    CHAPTER 1 EXECUTIVE SUMMARY 4
    Scope of the report 4
    Key findings 4
    Argentina 4
    Mexico 5
    IMS caveat 6
    CHAPTER 2 THE PHARMACEUTICAL MARKET IN ARGENTINA 11
    Argentina has stable macroeconomic factors, some of which must be strengthened 11
    A growing pharmaceutical market dominated by branded generics 12
    Demographic trends in Argentina 13
    Disease burden in Argentina 14
    Socioeconomic environment in Argentina 15
    Political climate in Argentina - stable 15
    GDP has been growing after the economic crisis of 2001 16
    Regional differences - the fight for equality continues 17
    Mercosur established free trade between the countries involved 18
    Corporate environment in Argentina 19
    Foreign direct investment in Argentina is modest 19
    Taxation system in Argentina 19
    The healthcare system in Argentina 21
    Healthcare expenditure in Argentina is high 23
    The public sector is decentralized 23
    Social health insurance system is fragmented 24
    The private sector covers a minority of the population 25
    The hospital capacity within the public sector has declined while the private sector has been growing 25
    Regulatory issues in Argentina 26
    IP protection has improved but is still inadequate 26
    A significant effort has been made to reduce the patent backlog in Argentina 27
    Registration of drugs in Argentina is a straight forward procedure 28
    Advertising of pharmaceuticals is strictly controlled 28
    Import of pharmaceuticals has been facilitated by Mercosur agreement 29
    Drug counterfeiting has been reduced by a number of measures 29
    Pricing and reimbursement of pharmaceuticals in Argentina 30
    Pricing of pharmaceuticals in Argentina 30
    The Generics Law, resulted in lower prices and increased access to pharmaceuticals 30
    Antiretroviral therapy prices were decreased 31
    Reimbursement of pharmaceuticals in Argentina 32
    Remediar program, introduced in 2002, increased drug access to the poor 33
    Pharmaceutical market dynamics in Argentina 34
    Branded generics dominate the Argentinean market 35
    Top three distributors dominate while retail pharmacy chains are expanding 37
    Top manufacturers on the Argentinean retail market 38
    Top ATC groups by sales value on the Argentinean retail market 39
    Top brands on the Argentinean retail market 42
    Import and export of pharmaceuticals - demand for foreign drugs remains high 43
    Major foreign pharmaceutical companies in Argentina 43
    Pfizer 43
    Bayer 44
    Roche 44
    Major domestic pharmaceutical companies in Argentina 44
    Roemmers 45
    Bagó - collaboration and geographical expansion are driving growth 45
    Phoenix 46
    Clinical trials in Argentina - an underused opportunity 47
    CHAPTER 3 THE PHARMACEUTICAL MARKET IN MEXICO 51
    Growth of the Mexican economy and strengthened intellectual property rights are boosting pharma industry 51
    The Mexican pharmaceutical market is dominated by foreign companies and is attracting a lot of clinical research 52
    Demographic trends in Mexico 53
    Disease burden in Mexico 54
    Socioeconomic environment in Mexico 55
    Political climate in Mexico 55
    GDP has increased since the introduction of NAFTA 56
    Regional differences - some rural areas are in extreme poverty 57
    NAFTA eliminated tariffs between the US, Canada and Mexico, and boosted the Mexican economy 57
    Corporate environment in Mexico 58
    Taxation system in Mexico 58
    Foreign direct investment in Mexico was boosted by NAFTA agreement 58
    The healthcare system in Mexico 60
    Healthcare system reforms in Mexico - the national health system aims to provide choice of healthcare provider 60
    Healthcare expenditure in Mexico is low 62
    The social security sector 62
    Governmental services headed by the Ministry of Health are designed to offer coverage to the poor and uninsured 63
    Only a small proportion of the population has private health insurance 63
    Regulatory issues in Mexico 64
    Intellectual property (IP) protection has significantly improved 64
    Registration of drugs in Mexico is simple 65
    Physicians play an important role in drug choices 66
    Import of pharmaceuticals in Mexico is facilitated by NAFTA 66
    Counterfeit drugs are a persistent problem in Mexico 67
    Pricing and reimbursement of pharmaceuticals in Mexico 67
    Pricing of pharmaceuticals in Mexico 67
    Reimbursement in Mexico 69
    Pharmaceutical market dynamics in Mexico 73
    Mexico classifies generics into three segments 74
    Market growth is driven mainly by growing preference and demand for high-value products and not by volume growth 74
    Distribution of pharmaceuticals in Mexico is dominated by two distributors 75
    Pharmacies selling cheap pharmaceuticals are very popular in Mexico 75
    Top pharmaceutical companies in Mexico-multinationals dominate 76
    Top ATC groups by sales value on the Mexican retail market 77
    Top brands on the Mexican retail market 80
    Import and export of pharmaceuticals have increased since NAFTA came into place 81
    Major foreign pharmaceutical companies in Mexico 81
    Sanofi-Aventis 82
    Pfizer 82
    AstraZeneca 82
    Major domestic pharmaceutical companies in Mexico 83
    Senosiain 83
    Clinical trials in Mexico - an attractive opportunity for US companies 84
    CHAPTER 4 BIBLIOGRAPHY 86
    Publications and online articles 86
    Datamonitor resources 96
    Glossary of Terms 97
    List of Tables
    Table 1: Demographic indicators for Argentina, 2005 13
    Table 2: Average annual growth rate of GDP and exports in Argentina, 1998-2010 (%), 16
    Table 3: Key economic indicators for Argentina, 1986-2006 17
    Table 4: Health expenditure indicators in Argentina, 2004 23
    Table 5: Density of healthcare workers and hospital capacity in Argentina, 1998 26
    Table 6: Argentina - Growth of pharmaceutical market in terms of sales volume, 2003-06 35
    Table 7: Argentina - Average cost of unit sold, 2003-06 35
    Table 8: Branded generics dominate the Argentinean pharmaceutical market, 2006 36
    Table 9: Top 15 drug manufacturers in Argentina, 2006 38
    Table 10: Market segmentation in Argentina according to ATC groups, 2006 39
    Table 11: Top 15 brands in Argentina, 2006 42
    Table 12: Key demographic indicators for Mexico, 2005 53
    Table 13: Mexico -average annual growth rates of GDP and exports (%), 1986-2010 56
    Table 14: Key economic indicators for Mexico, 1986-2006 57
    Table 15: Health expenditure indicators in Mexico, 2004 62
    Table 16: Growth of the Mexican market in terms of sales volume, 2003-06 74
    Table 17: Average cost of unit sold, 2003-06 75
    Table 18: Top 15 drug manufacturers in Mexico in 2006 76
    Table 19: Growth of ATC group split in the Mexican market, 2006 77
    Table 20: Top 15 brands in 2006 in Mexico 80
    List of Figures
    Figure 1: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical industry in Argentina, 2008 11
    Figure 2: Pharmaceutical market dynamics in Argentina, 2008 12
    Figure 3: Structure of health system financing and provision in Argentina 22
    Figure 4: The size of the Argentinean retail pharmaceutical market, 2002-06 34
    Figure 5: Sales growth and CAGR for the top ATC groups in Argentina 40
    Figure 6: The relative market share for each ATC group in Argentina is very similar to the six major markets 41
    Figure 7: Clinical trial protocols assessed and approved, 1994-2006 48
    Figure 8: Multinational pharmaceutical companies sponsor the majority of clinical research in Argentina 49
    Figure 9: Advantages and disadvantages of carrying out clinical trials in Argentina 50
    Figure 10: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical industry in Mexico 51
    Figure 11: Pharmaceutical market dynamics in Mexico 52
    Figure 12: The three pricing regulations in Mexico 69
    Figure 13: Decision process for listing pharmaceuticals on the Basic Formulary and the Catalogue of Inputs 71
    Figure 14: The size of the Mexican retail pharmaceutical market, 2002-06 73
    Figure 15: Sales growth and CAGR for the top ATC groups in Mexico, 2006 78
    Figure 16: The relative market shares of each ATC groups are very similar between Mexico and the six major markets 79
    Figure 17: Advantages and disadvantages of carrying out clinical trials in Mexico 85


    New Search:

    PPLSEN